OptimizeRx Co. (NASDAQ:OPRX - Free Report) - Stock analysts at B. Riley issued their Q1 2025 earnings per share estimates for OptimizeRx in a research report issued to clients and investors on Wednesday, March 12th. B. Riley analyst A. Schock anticipates that the company will earn ($0.34) per share for the quarter. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for OptimizeRx's current full-year earnings is ($0.33) per share. B. Riley also issued estimates for OptimizeRx's Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.19 EPS and FY2025 earnings at ($0.27) EPS.
OPRX has been the subject of a number of other research reports. Lake Street Capital restated a "buy" rating and issued a $11.00 price objective on shares of OptimizeRx in a research note on Tuesday, December 24th. Stephens assumed coverage on OptimizeRx in a research note on Friday, December 20th. They issued an "equal weight" rating and a $5.50 price objective for the company. JMP Securities restated a "market outperform" rating and issued a $8.00 price objective on shares of OptimizeRx in a research note on Thursday, February 6th. Finally, Royal Bank of Canada restated a "sector perform" rating and issued a $6.00 price objective (down previously from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $9.06.
Get Our Latest Stock Report on OPRX
OptimizeRx Stock Performance
NASDAQ:OPRX traded up $0.08 during trading on Monday, reaching $8.69. The company's stock had a trading volume of 769,705 shares, compared to its average volume of 255,459. The firm has a market cap of $160.08 million, a price-to-earnings ratio of -6.59 and a beta of 1.31. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The firm has a 50 day moving average of $5.71 and a 200-day moving average of $5.92. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $14.13.
Insider Activity
In related news, Director James Paul Lang acquired 321,408 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the acquisition, the director now owns 389,452 shares of the company's stock, valued at approximately $2,959,835.20. This trade represents a 472.35 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 6.10% of the company's stock.
Institutional Trading of OptimizeRx
A number of institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets lifted its holdings in OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company's stock worth $28,000 after purchasing an additional 2,414 shares in the last quarter. Wells Fargo & Company MN increased its stake in OptimizeRx by 33.3% in the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock worth $54,000 after acquiring an additional 2,797 shares during the last quarter. Barclays PLC increased its stake in OptimizeRx by 13.5% in the 4th quarter. Barclays PLC now owns 30,574 shares of the company's stock worth $148,000 after acquiring an additional 3,640 shares during the last quarter. Perkins Capital Management Inc. increased its stake in OptimizeRx by 4.4% in the 4th quarter. Perkins Capital Management Inc. now owns 105,813 shares of the company's stock worth $514,000 after acquiring an additional 4,450 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in OptimizeRx by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 400,621 shares of the company's stock worth $1,948,000 after acquiring an additional 4,821 shares during the last quarter. Hedge funds and other institutional investors own 76.47% of the company's stock.
OptimizeRx Company Profile
(
Get Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Read More
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
